Related references
Note: Only part of the references are listed.Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
Giorgio Scagliotti et al.
INVESTIGATIONAL NEW DRUGS (2016)
ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2)
Y. Jiang et al.
BLOOD CANCER JOURNAL (2016)
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells
Jana Zemanova et al.
ONCOTARGET (2016)
Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo
Wenxiu Qi et al.
CANCER BIOLOGY & THERAPY (2015)
Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
Khanh Do et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia
Ilaria Iacobucci et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Ataxia-telangiectasia - A historical review and a proposal for a new designation: ATM syndrome
Helio A. G. Teive et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway
Marwan Kwok et al.
LANCET (2015)
Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL+ leukemia cells
Tri Nguyen et al.
LEUKEMIA RESEARCH (2015)
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias
Nidal Muvarak et al.
MOLECULAR CANCER RESEARCH (2015)
LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
Constance King et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente et al.
NATURE (2015)
ATM and ATR as therapeutic targets in cancer
Anika Maria Weber et al.
PHARMACOLOGY & THERAPEUTICS (2015)
AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair
James B. Ford et al.
ONCOTARGET (2015)
Chemopreventive Effects of Korean Red Ginseng Extract on Rat Hepatocarcinogenesis
Hyemee Kim et al.
JOURNAL OF CANCER (2015)
A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
L. Zhou et al.
LEUKEMIA (2015)
CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress
L. M. Sarmento et al.
ONCOGENE (2015)
DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer
Denis Velic et al.
BIOMOLECULES (2015)
Chemotherapy induced microsatellite instability and loss of heterozygosity in chromosomes 2, 5, 10, and 17 in solid tumor patients
Nasir Kamat et al.
CANCER CELL INTERNATIONAL (2014)
ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses
Rozenn Josse et al.
CANCER RESEARCH (2014)
Targeting ATR in DNA damage response and cancer therapeutics
Emmanouil Fokas et al.
CANCER TREATMENT REVIEWS (2014)
CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo
Leena Chaudhuri et al.
HAEMATOLOGICA (2014)
Radiosensitization of Human Leukemic HL-60 Cells by ATR Kinase Inhibitor (VE-821): Phosphoproteomic Analysis
Barbora Salovska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
Constance King et al.
INVESTIGATIONAL NEW DRUGS (2014)
CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells
Wenxiu Qi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Amy B. Hall et al.
ONCOTARGET (2014)
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
Cynthia X. Ma et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma
Mike R. Russell et al.
CANCER RESEARCH (2013)
Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776
Carl G. Engelke et al.
CLINICAL CANCER RESEARCH (2013)
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Shuhui Lim et al.
DEVELOPMENT (2013)
ATM-dependent DNA damage-response pathway as a determinant in chronic myelogenous leukemia
Masatoshi Takagi et al.
DNA REPAIR (2013)
Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer
Michael A. Batey et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair
Yun Dai et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality
Annemie A. Van Linden et al.
MOLECULAR CANCER THERAPEUTICS (2013)
CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells
Svetlana Grabauskiene et al.
LUNG CANCER (2013)
The ATM protein kinase: regulating the cellular response to genotoxic stress, and more
Yosef Shiloh et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells
S. Origanti et al.
ONCOGENE (2013)
Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60)
Jirina Vavrova et al.
RADIATION AND ENVIRONMENTAL BIOPHYSICS (2013)
RNAi screening of the kinome with cytarabine in leukemias
Raoul Tibes et al.
BLOOD (2012)
Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing
Anna Dolnik et al.
BLOOD (2012)
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
I. M. Pires et al.
BRITISH JOURNAL OF CANCER (2012)
Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype
Christine Didier et al.
CANCER BIOLOGY & THERAPY (2012)
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy
Remko Prevo et al.
CANCER BIOLOGY & THERAPY (2012)
Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition
Amy D. Guertin et al.
CANCER CELL INTERNATIONAL (2012)
Inhibition of ATM blocks the etoposide-induced DNA damage response and apoptosis of resting human T cells
Z. Korwek et al.
DNA REPAIR (2012)
ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter
Davide Rossi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
Jenny M. Kreahling et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells
Heather J. Landau et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
E. Fokas et al.
CELL DEATH & DISEASE (2012)
DNA repair dysregulation from cancer driver to therapeutic target
Nicola J. Curtin
NATURE REVIEWS CANCER (2012)
MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
Kathleen A. Bridges et al.
CLINICAL CANCER RESEARCH (2011)
Autophosphorylation and ATM Activation ADDITIONAL SITES ADD TO THE COMPLEXITY
Sergei V. Kozlov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Thr-1989 Phosphorylation Is a Marker of Active Ataxia Telangiectasia-mutated and Rad3-related (ATR) Kinase
Edward A. Nam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents
Jean-Damien Charrier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
ATR Autophosphorylation as a Molecular Switch for Checkpoint Activation
Shizhou Liu et al.
MOLECULAR CELL (2011)
Adult Acute Lymphoblastic Leukemia Concepts and Strategies
Stefan Faderl et al.
CANCER (2010)
MK-1775, a small molecule Wee1 inhibitor, enhances antitumor efficacy of various DNA-damaging agents, including 5-fluorouracil
Hiroshi Hirai et al.
CANCER BIOLOGY & THERAPY (2010)
Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2 Checkpoint and Inhibition of Homologous Recombinational DNA Repair
Meredith A. Morgan et al.
CANCER RESEARCH (2010)
The MRN complex in double-strand break repair and telomere maintenance
Brandon J. Lamarche et al.
FEBS LETTERS (2010)
Genomic instability - an evolving hallmark of cancer
Simona Negrini et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas
J. Bartkova et al.
ONCOGENE (2010)
Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy
Cindy Cavelier et al.
CANCER RESEARCH (2009)
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The DNA-damage response in human biology and disease
Stephen P. Jackson et al.
NATURE (2009)
Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response
Hiroshi Nishida et al.
NUCLEIC ACIDS RESEARCH (2009)
ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia
J. Grosjean-Raillard et al.
ONCOGENE (2009)
Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms
A. Satyanarayana et al.
ONCOGENE (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair
Annahita Sallmyr et al.
CANCER LETTERS (2008)
Mre11 dimers coordinate DNA end bridging and nuclease processing in double-strand-break repair
R. Scott Williams et al.
CELL (2008)
Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer
Martin F. Lavin
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
An oncogene-induced DNA damage model for cancer development
Thanos D. Halazonetis et al.
SCIENCE (2008)
UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium
Stephen Welch et al.
GYNECOLOGIC ONCOLOGY (2007)
Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template
R. Scott Williams et al.
BIOCHEMISTRY AND CELL BIOLOGY (2007)
Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells
Kyu-Tae Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Cdc25 and Wee1: analogous opposites?
Jennifer A. Perry et al.
CELL DIVISION (2007)
A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers
Deborah Thompson et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage
Estelle Schmitt et al.
JOURNAL OF CELL SCIENCE (2006)
Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia
Matthew F. Rudd et al.
BLOOD (2006)
ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks
Margaret Nieborowska-Skorska et al.
CELL CYCLE (2006)
Stabilizers and destabilizers controlling cell cycle oscillators
D Guardavaccaro et al.
MOLECULAR CELL (2006)
ATM regulates ATR chromatin loading in response to DNA double-strand breaks
M Cuadrado et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Dissecting p53-dependent apoptosis
J. E. Chipuk et al.
CELL DEATH AND DIFFERENTIATION (2006)
Cyclin-dependent kinase (CDK) phosphorylation destabilizes somatic Wee1 via multiple pathways
N Watanabe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint
TS Byun et al.
GENES & DEVELOPMENT (2005)
ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex
JH Lee et al.
SCIENCE (2005)
Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage
J Falck et al.
NATURE (2005)
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM
I Hickson et al.
CANCER RESEARCH (2004)
Requirement of the MRN complex for ATM activation by DNA damage
T Uziel et al.
EMBO JOURNAL (2003)
Regulating mammalian checkpoints through Cdc25 inactivation
M Donzelli et al.
EMBO REPORTS (2003)
Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes
L Zou et al.
SCIENCE (2003)
Chk1 and Chk2 kinases in checkpoint control and cancer
J Bartek et al.
CANCER CELL (2003)
Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance
EJ Brown et al.
GENES & DEVELOPMENT (2003)
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
CJ Bakkenist et al.
NATURE (2003)
Nbs1 promotes ATM dependent phosphorylation events including those required for G1/S arrest
PM Girard et al.
ONCOGENE (2002)
To the editor: Mutations of Chk2 in primary hematopoietic neoplasms
A Hangaishi et al.
BLOOD (2002)
Oxygen metabolism causes chromosome breaks and is associated with the neuronal apoptosis observed in DNA double-strand break repair mutants
ZE Karanjawala et al.
CURRENT BIOLOGY (2002)
Measurement and analysis of the chemotherapy-induced genetic instability in pediatric cancer patients
RL de Mesa et al.
MUTAGENESIS (2002)
Human Rad50/Mre11 is a flexible complex that can tether DNA ends
M de Jager et al.
MOLECULAR CELL (2001)
Investigation on the role of the ATM gene in chronic myeloid leukaemia
JV Melo et al.
LEUKEMIA (2001)
Cdc25B activity is regulated by 14-3-3
A Forrest et al.
ONCOGENE (2001)
Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias
WK Hofmann et al.
LEUKEMIA RESEARCH (2001)
DNA damage-dependent nuclear dynamics of the Mre11 complex
OK Mirzoeva et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Emergence of genetic instability in children treated for leukemia
BA Finette et al.
SCIENCE (2000)
Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice
A de Klein et al.
CURRENT BIOLOGY (2000)
Share Paper
